Efficiency ustekinumab in the treatment of patients with psoriasis with metabolic disorders
One of the goals of psoriasis therapy is to achieve sustainable remission. Currently, genetically engineered biological drugs are most effective in the treatment of psoriasis. However, there is a certain proportion of patients with insufficient efficiency of genetic engineering biological therapy. O...
Main Authors: | I. V. Rychkova, O. A. Prytulo |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2019-08-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/3144 |
Similar Items
-
Effectiveness of resuming ustekinumab therapy in psoriasis patients with metabolic disorders. Clinical experience
by: I. V. Rychkova, et al.
Published: (2019-02-01) -
Changes in metabolic parameters in psoriasis patients treated with interleukin-12/23 blockade (ustekinumab)
by: Chau Yee Ng, et al.
Published: (2020-01-01) -
Ustekinumab treats psoriasis by suppressing RORC and T-box but its suppression of GATA restrains its efficacy
by: Lun-Fei Liu, et al.
Published: (2019-04-01) -
Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis
by: Maeve Lynch, MD, MBBChBAO, et al.
Published: (2017-05-01) -
Ustekinumab in Real-Life Practice: Experience in 116 Patients with Moderate-To-Severe Psoriasis
by: Inês Raposo, et al.
Published: (2019-03-01)